GO:0017109 glutamate-cysteine ligase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0017109 (glutamate-cysteine ligase complex) is the cellular component that catalyzes the first and rate-limiting step of glutathione biosynthesis, ligating L-glutamate to L-cysteine to form gamma-L-glutamyl-L-cysteine.
• The complex is a heterodimer of a catalytic subunit (GCLC) and a modifier subunit (GCLM) that modulates catalytic efficiency and redox regulation.
• Loss of glutamate-cysteine ligase function depletes cellular glutathione, sensitizing cells to oxidative stress and ferroptosis.
• Glutamate-cysteine ligase is required for normal neurodevelopment; its deficiency causes oxidative neuropathology in tuberous sclerosis complex models.
• In cancer, glutamate-cysteine ligase activity supports tumor survival, metabolic adaptation, and resistance to ferroptosis.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of GCLC/GCLM function in disease and drug response.
Description
The glutamate-cysteine ligase complex (GO:0017109) is a cellular component defined by its enzymatic activity: the ligation of L-glutamate to L-cysteine to form gamma-L-glutamyl-L-cysteine, the first and rate-limiting step in glutathione (GSH) synthesis. This complex is essential for maintaining cellular redox homeostasis, detoxification, and protection against oxidative damage. Because glutathione is the most abundant non-enzymatic antioxidant in mammalian cells, the glutamate-cysteine ligase complex sits at the center of cellular defense against reactive oxygen species and electrophilic stress. Researchers study GO:0017109 to understand how cells adapt to oxidative stress, how glutathione depletion contributes to disease, and how modulating this complex can alter cell survival, ferroptosis sensitivity, and drug resistance. The complex is a heterodimer composed of a catalytic subunit (GCLC) and a modifier subunit (GCLM), and its activity is regulated at multiple levels, including substrate availability, redox state, and protein-protein interactions. In cancer, adipocyte-derived glutathione can promote obesity-related breast cancer by regulating the SCARB2-ARF1-mTORC1 complex, highlighting the systemic importance of glutathione synthesis. In melanoma, the lymph node environment drives FSP1 targetability, linking glutathione metabolism to metastatic survival. In hepatocellular carcinoma, ISG15 enhances the activity of gamma-glutamate cysteine ligase to suppress apoptosis under high-fat diet conditions, and the acetyltransferase ARD1 induces glutathione synthesis to facilitate ferroptosis evasion. These findings underscore the broad relevance of GO:0017109 across oncology, neuroscience, and metabolic disease.
glutamate-cysteine ligase complex At A Glance
| GO ID | GO:0017109 |
|---|---|
| GO term | glutamate-cysteine ligase complex |
| Ontology | cellular_component |
| Synonym | gamma-glutamylcysteine synthetase complex |
| Major function | Catalyzes the ligation of L-glutamate to L-cysteine to form gamma-L-glutamyl-L-cysteine, the rate-limiting step in glutathione synthesis. |
| Subunits | Heterodimer of catalytic subunit GCLC and modifier subunit GCLM. |
| Cofactor | ATP-dependent; requires magnesium ions. |
| Pathway | Glutathione biosynthesis; oxidative stress response. |
| Disease relevance | Cancer, neurodegeneration, ferroptosis, metabolic disorders. |
What Is GO:0017109?
The glutamate-cysteine ligase complex is an enzyme complex that catalyzes the ATP-dependent ligation of L-glutamate to L-cysteine, forming gamma-L-glutamyl-L-cysteine, also known as gamma-glutamylcysteine. This reaction is the first and rate-limiting step in glutathione biosynthesis. The complex is a heterodimer consisting of a catalytic subunit (GCLC) and a modifier subunit (GCLM), and it is also known as gamma-glutamylcysteine synthetase complex.
Why Is glutamate-cysteine ligase complex Important in Cell Biology?
The glutamate-cysteine ligase complex is critically important because it controls the rate-limiting step of glutathione synthesis, thereby governing cellular redox balance, detoxification capacity, and survival under oxidative stress. Dysregulation of this complex is implicated in cancer progression, where elevated glutathione supports tumor growth and ferroptosis evasion, and in neurodegenerative conditions where oxidative damage contributes to pathology. Understanding GO:0017109 is therefore essential for developing therapeutic strategies that target glutathione metabolism.
• Rate-limiting enzyme for glutathione synthesis, the major cellular antioxidant.
• Protects cells from oxidative stress and electrophilic damage.
• Modulates ferroptosis sensitivity in cancer cells.
• Supports metabolic adaptation in obesity-related breast cancer.
• Required for normal neurodevelopment; deficiency causes neuropathology.
• Regulated by ISG15 in hepatocellular carcinoma to suppress apoptosis.
• Targeted by ARD1-mediated acetylation to promote ferroptosis evasion.
• Involved in lymph node metastatic melanoma survival via FSP1.
• Potential therapeutic target for acetaminophen hepatotoxicity.
• Key node in integrative RNA profiling of viral infections.
What Happens During glutamate-cysteine ligase complex?
Substrate Binding and Activation
In simple terms: The complex grabs glutamate and cysteine and uses ATP to join them together.
The catalytic subunit GCLC binds L-glutamate and L-cysteine in an ATP-dependent manner. ATP is hydrolyzed to ADP and phosphate, activating the glutamate gamma-carboxyl group for nucleophilic attack by the amino group of cysteine. This step is the first and rate-limiting reaction in glutathione biosynthesis.
Formation of gamma-Glutamylcysteine
In simple terms: The two amino acids are linked to form a dipeptide called gamma-glutamylcysteine.
The ligation of L-glutamate to L-cysteine yields gamma-L-glutamyl-L-cysteine (gamma-Glu-Cys), which is the immediate precursor for glutathione. This dipeptide is subsequently combined with glycine by glutathione synthetase to form reduced glutathione (GSH).
Regulation by the Modifier Subunit GCLM
In simple terms: A helper protein called GCLM makes the enzyme work better and respond to oxidative stress.
The modifier subunit GCLM associates with GCLC to form the heterodimeric complex. GCLM lowers the Km for glutamate and increases the catalytic efficiency of GCLC, and it also modulates the sensitivity of the complex to feedback inhibition by glutathione. This regulation is critical for adapting glutathione synthesis to cellular redox status.
Redox Regulation and Feedback Inhibition
In simple terms: When glutathione levels are high, the complex slows down; when oxidative stress rises, it speeds up.
Glutathione feedback-inhibits the glutamate-cysteine ligase complex, preventing overaccumulation. Under oxidative stress, the complex is activated through post-translational modifications and increased substrate availability. ISG15 has been shown to enhance the activity of gamma-glutamate cysteine ligase to suppress apoptosis in high-fat diet-promoted hepatocellular carcinoma. The acetyltransferase ARD1 induces glutathione synthesis to facilitate ferroptosis evasion, further linking regulation of this complex to cancer cell survival.
Key Genes Involved in GO:0017109 glutamate-cysteine ligase complex
The following genes encode subunits, regulators, and interacting proteins of the glutamate-cysteine ligase complex and related glutathione metabolism pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCLC | Catalytic subunit of glutamate-cysteine ligase complex | Rate-limiting enzyme for glutathione synthesis; knockout causes oxidative stress sensitivity. |
| GCLM | Modifier subunit of glutamate-cysteine ligase complex | Regulates catalytic efficiency and feedback inhibition; knockout alters glutathione levels. |
| GSS | Glutathione synthetase; converts gamma-Glu-Cys to GSH | Downstream of GO:0017109; deficiency causes glutathione synthetase deficiency. |
| ISG15 | Enhances gamma-glutamate cysteine ligase activity | Suppresses apoptosis in high-fat diet-promoted hepatocellular carcinoma. |
| ARD1 | Acetyltransferase that induces glutathione synthesis | Facilitates ferroptosis evasion in hepatocellular carcinoma. |
| SCARB2 | Receptor involved in adipocyte-derived glutathione signaling | Regulates SCARB2-ARF1-mTORC1 complex in obesity-related breast cancer. |
| ARF1 | Small GTPase in vesicular trafficking | Part of SCARB2-ARF1-mTORC1 complex affected by glutathione. |
| mTORC1 | Kinase complex regulating metabolism | Downstream of glutathione signaling in obesity-related breast cancer. |
| FSP1 | Ferroptosis suppressor protein 1 | Targetable in lymph node metastatic melanoma; linked to glutathione metabolism. |
| TSC1 | Tuberous sclerosis complex subunit | TSC neuropathology requires glutamate-cysteine ligase. |
| TSC2 | Tuberous sclerosis complex subunit | TSC neuropathology requires glutamate-cysteine ligase. |
| NFE2L2 | Transcription factor NRF2; regulates antioxidant response | Controls expression of GCLC and GCLM. |
| KEAP1 | Negative regulator of NRF2 | Modulates NRF2-mediated antioxidant gene expression. |
| GPX4 | Glutathione peroxidase 4; uses GSH to detoxify lipid peroxides | Ferroptosis regulator; depends on glutathione synthesized via GO:0017109. |
| SLC7A11 | Cystine/glutamate antiporter | Supplies cysteine for glutathione synthesis; regulates ferroptosis. |
| G6PD | Glucose-6-phosphate dehydrogenase | Generates NADPH for glutathione recycling; linked to oxidative stress. |
| TXN | Thioredoxin | Redox regulator interacting with glutathione system. |
How Is glutamate-cysteine ligase complex Regulated?
The glutamate-cysteine ligase complex is regulated at multiple levels. Transcriptionally, NRF2 (NFE2L2) induces GCLC and GCLM expression in response to oxidative stress. Post-translationally, ISG15 enhances gamma-glutamate cysteine ligase activity to suppress apoptosis in high-fat diet-promoted hepatocellular carcinoma. The acetyltransferase ARD1 induces glutathione synthesis to facilitate ferroptosis evasion in hepatocellular carcinoma. Additionally, mTORC1 signaling is influenced by adipocyte-derived glutathione via the SCARB2-ARF1-mTORC1 complex in obesity-related breast cancer. In melanoma, the lymph node environment drives FSP1 targetability, linking glutathione metabolism to metastatic survival.
glutamate-cysteine ligase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCLC | Cancer, oxidative stress, ferroptosis | CRISPR knockout in cancer cell lines; point mutation of catalytic residues. |
| GCLM | Cancer, neurodegeneration | Knockout and overexpression models to modulate glutathione levels. |
| ISG15 | Hepatocellular carcinoma | Knockout and knock-in models to study ISG15-mediated GCL activation. |
| ARD1 | Hepatocellular carcinoma, ferroptosis evasion | CRISPR knockout and overexpression in liver cancer cells. |
| TSC1/TSC2 | Tuberous sclerosis complex neuropathology | Conditional knockout mouse models; patient-derived iPSCs. |
Cancer and Ferroptosis Evasion
Elevated glutathione synthesis via the glutamate-cysteine ligase complex supports tumor survival and ferroptosis evasion. In hepatocellular carcinoma, ISG15 enhances gamma-glutamate cysteine ligase activity to suppress apoptosis under high-fat diet conditions. The acetyltransferase ARD1 induces glutathione synthesis to facilitate ferroptosis evasion. Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2-ARF1-mTORC1 complex. In melanoma, the lymph node environment drives FSP1 targetability, linking glutathione metabolism to metastatic survival.
Neurodegeneration and Neuropathology
Tuberous sclerosis complex (TSC) neuropathology requires glutamate-cysteine ligase, and its deficiency leads to oxidative stress and neuronal damage. Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors, including glutathione metabolism genes. Age-related decline in cellular glutathione is associated with glutamate cysteine ligase dysfunction, and gamma-glutamylcysteine has therapeutic potential.
Liver Injury and Drug Toxicity
Acetaminophen hepatotoxicity is exacerbated by glutathione depletion, and the glutamate-cysteine ligase complex is critical for replenishing glutathione. Recommendations for the use of the acetaminophen hepatotoxicity model highlight the importance of this pathway in mechanistic studies.
From glutamate-cysteine ligase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GCLC loss sensitize cancer cells to ferroptosis? | GCLC knockout cell lines treated with ferroptosis inducers. |
| How does GCLM modulate glutathione feedback inhibition? | GCLM point-mutation knock-in models. |
| Can ISG15 enhance GCL activity in vivo? | ISG15 overexpression and knockout mouse models. |
| What is the role of ARD1 in glutathione synthesis? | ARD1 knockout and overexpression in hepatocellular carcinoma cells. |
| How does adipocyte-derived glutathione affect breast cancer? | Co-culture models with adipocytes and SCARB2 knockout. |
| Does FSP1 targeting depend on lymph node environment? | Melanoma metastasis models with FSP1 knockout. |
How to Study the glutamate-cysteine ligase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality and drug sensitivity | Identify modulators of ferroptosis and glutathione synthesis. |
| RNA-seq | Transcriptional changes | Profile glutathione pathway genes in disease models. |
| Proteomics | Protein abundance and modifications | Detect ISG15 conjugation and acetylation of GCL subunits. |
| Glutathione assay | Total and reduced glutathione levels | Assess GCL activity in knockout or overexpression cells. |
| GCL enzymatic activity assay | Rate of gamma-glutamylcysteine formation | Measure catalytic efficiency of GCLC/GCLM variants. |
| Western blot | Protein expression and post-translational modifications | Validate knockout and overexpression models. |
| Immunofluorescence | Subcellular localization | Visualize GCLC/GCLM in cells. |
| Metabolomics | Global metabolite changes | Link GCL function to metabolic reprogramming. |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to glutathione depletion or ferroptosis inducers. Such screens have revealed the importance of GCLC, GCLM, and related pathway components in cancer cell survival.
RNA Sequencing and Integrative Profiling
RNA-seq of TBEV-infected neurons and astrocytes revealed potential pathogenic effectors, including glutathione metabolism genes, highlighting the utility of transcriptomics in studying GO:0017109.
Proteomics and Post-Translational Modification Analysis
Mass spectrometry-based proteomics can identify ISG15 conjugation and ARD1-mediated acetylation of glutamate-cysteine ligase subunits, providing mechanistic insights into regulation.
Metabolic and Redox Assays
Glutathione levels, GCL enzymatic activity, and reactive oxygen species can be measured using colorimetric, fluorometric, or HPLC-based assays to assess the functional impact of genetic perturbations.
How CRISPR Can Be Used to Study GO:0017109 glutamate-cysteine ligase complex
Knockout
CRISPR knockout of GCLC or GCLM depletes glutathione, sensitizing cells to oxidative stress and ferroptosis. Such models are used to study cancer cell vulnerabilities and neuropathology.
Point Mutation
Point mutations in catalytic residues of GCLC or in regulatory domains of GCLM can dissect enzymatic mechanism and feedback inhibition. These models are valuable for understanding how specific amino acids contribute to catalysis.
Knock-in
Knock-in of tagged GCLC or GCLM (e.g., FLAG, HA) enables affinity purification and interactome analysis. Knock-in of disease-associated mutations can model human variants.
Overexpression
Overexpression of GCLC, GCLM, or ISG15 increases glutathione synthesis and protects cells from apoptosis. These models are used to study ferroptosis evasion and drug resistance.
How EDITGENE Supports glutamate-cysteine ligase complex Research
Researchers studying glutamate-cysteine ligase complex-related genes often need to determine whether a candidate gene is causally involved in glutathione metabolism, oxidative stress response, or ferroptosis. EDITGENE provides comprehensive CRISPR gene editing services to create precisely tailored cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for glutamate-cysteine ligase complex research.
Frequently Asked Questions About glutamate-cysteine ligase complex
What is the glutamate-cysteine ligase complex?
The glutamate-cysteine ligase complex (GO:0017109) is an enzyme complex that catalyzes the ligation of L-glutamate to L-cysteine to form gamma-L-glutamyl-L-cysteine, the rate-limiting step in glutathione synthesis.
What genes are involved in the glutamate-cysteine ligase complex?
The complex is composed of a catalytic subunit encoded by GCLC and a modifier subunit encoded by GCLM. Other related genes include GSS, ISG15, ARD1, and NFE2L2.
What is the function of GO:0017109?
GO:0017109 functions in glutathione biosynthesis, specifically catalyzing the first and rate-limiting step. It is essential for cellular redox homeostasis and protection against oxidative stress.
How is the glutamate-cysteine ligase complex regulated?
It is regulated transcriptionally by NRF2, post-translationally by ISG15 and ARD1, and through feedback inhibition by glutathione.
What diseases are associated with glutamate-cysteine ligase complex dysfunction?
Dysfunction is linked to cancer, ferroptosis evasion, neurodegeneration, tuberous sclerosis complex, and acetaminophen hepatotoxicity.
How can I study the glutamate-cysteine ligase complex using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the roles of GCLC and GCLM in glutathione synthesis and disease.
What is the role of GCLC in cancer?
GCLC supports glutathione synthesis, protecting cancer cells from oxidative stress and ferroptosis, and its inhibition may sensitize tumors to therapy.
What is the role of GCLM in the glutamate-cysteine ligase complex?
GCLM is the modifier subunit that enhances catalytic efficiency and modulates feedback inhibition by glutathione.
How does ISG15 affect glutamate-cysteine ligase?
ISG15 enhances the activity of gamma-glutamate cysteine ligase to suppress apoptosis in high-fat diet-promoted hepatocellular carcinoma.
What research methods are used to study GO:0017109?
Common methods include CRISPR screening, RNA-seq, proteomics, glutathione assays, and enzymatic activity assays.
Conclusion
The glutamate-cysteine ligase complex (GO:0017109) is a central regulator of glutathione synthesis and cellular redox homeostasis. Its dysfunction is implicated in cancer, neurodegeneration, and metabolic disease, making it a compelling target for therapeutic intervention. Advances in CRISPR gene editing and multi-omics profiling continue to unravel the complex regulation and disease relevance of this enzyme complex. EDITGENE offers a comprehensive suite of CRISPR services to support mechanistic and translational research on GO:0017109.
References
- 1. Zhao C et al.. 2025. Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2-ARF1-mTORC1 complex.. Cell Metab 37(3):692-707.e9 PMID: 39442522
- 2. Palma M et al.. 2026. Lymph node environment drives FSP1 targetability in metastasizing melanoma.. Nature 649(8096):477-486 PMID: 41193799
- 3. Jaeschke H et al.. 2021. Recommendations for the use of the acetaminophen hepatotoxicity model for mechanistic studies and how to avoid common pitfalls.. Acta Pharm Sin B 11(12):3740-3755 PMID: 35024303
- 4. Liu X et al.. 2025. ISG15 Enhances the Activity of γ-Glutamate Cysteine Ligase to Suppress Apoptosis in High Fat Diet-Promoted Hepatocellular Carcinoma.. Adv Sci (Weinh) 12(19):e2416401 PMID: 40126377
- 5. Ferguson G et al.. 2016. Glutamate cysteine ligase and the age-related decline in cellular glutathione: The therapeutic potential of γ-glutamylcysteine.. Arch Biochem Biophys 593:12-23 PMID: 26845022
- 6. Selinger M et al.. 2022. Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.. Comput Struct Biotechnol J 20:2759-2777 PMID: 35685361
- 7. Liu Y et al.. 2025. The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma.. Cancer Res 85(21):4212-4232 PMID: 40838989
- 8. Malik AR et al.. 2015. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.. Acta Neuropathol Commun 3:48 PMID: 26220190
